0OP0 Stock Overview A specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
OptiNose, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for OptiNose Historical stock prices Current Share Price US$5.76 52 Week High US$26.70 52 Week Low US$0.15 Beta -0.15 1 Month Change -16.52% 3 Month Change -36.00% 1 Year Change -65.41% 3 Year Change -78.67% 5 Year Change -95.08% Change since IPO -97.58%
Recent News & Updates
New minor risk - Profitability Jan 03
Forecast breakeven date pushed back to 2027 Jan 03
New major risk - Share price stability Nov 16
New minor risk - Market cap size Nov 13
Third quarter 2024 earnings released: EPS: US$0.002 (vs US$0.083 loss in 3Q 2023) Nov 13
OptiNose, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06 See more updates
New minor risk - Profitability Jan 03
Forecast breakeven date pushed back to 2027 Jan 03
New major risk - Share price stability Nov 16
New minor risk - Market cap size Nov 13
Third quarter 2024 earnings released: EPS: US$0.002 (vs US$0.083 loss in 3Q 2023) Nov 13
OptiNose, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06
OptiNose Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 17
New minor risk - Market cap size Oct 11
Optinose Appoints Terry Kohler as Chief Financial Officer Oct 08
Second quarter 2024 earnings released: US$0.051 loss per share (vs US$0.023 profit in 2Q 2023) Aug 09
OptiNose, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
CEO & Director recently sold €116k worth of stock Jul 19 OptiNose, Inc.(NasdaqGS:OPTN) dropped from Russell Small Cap Completeness Index OptiNose, Inc. announced that it has received $4.68 million in funding May 22
First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.17 loss in 1Q 2023) May 15
New minor risk - Shareholder dilution May 12
OptiNose, Inc. to Report Q1, 2024 Results on May 14, 2024 May 12
OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024 May 10
OptiNose, Inc., Annual General Meeting, Jun 06, 2024 Apr 28
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025 Apr 26
Full year 2023 earnings released: US$0.32 loss per share (vs US$0.87 loss in FY 2022) Mar 08
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024 Mar 07
New minor risk - Profitability Mar 07
OptiNose, Inc. to Report Q4, 2023 Results on Mar 07, 2024 Mar 01
New minor risk - Insider selling Feb 03
CEO & Director recently sold €64k worth of stock Feb 02
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology Jan 19
Forecast to breakeven in 2026 Dec 31
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE Dec 06
OptiNose, Inc. Revises Revenue Guidance for the Full Year of 2023 Nov 10
Forecast to breakeven in 2025 Nov 10
OptiNose, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 28
Second quarter 2023 earnings released: EPS: US$0.023 (vs US$0.23 loss in 2Q 2022) Aug 11
OptiNose, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
New minor risk - Profitability Jul 11
No longer forecast to breakeven Jul 10
OptiNose, Inc. Approves Board Changes Jun 15
First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.31 loss in 1Q 2022) May 12
Optinose, Inc. Provides Revenue Guidance for Full Year of 2023 May 12
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE May 05
Full year 2022 earnings released: US$0.87 loss per share (vs US$1.45 loss in FY 2021) Mar 08 Optinose Announces Board Changes
Optinose Announces Departure of Michele Janis as Acting Chief Financial Officer Dec 10
No longer forecast to breakeven Nov 26 OptiNose, Inc. has completed a Follow-on Equity Offering in the amount of $50.008 million. Nov 22
Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.32 loss in 3Q 2021) Nov 16
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.32 loss in 3Q 2021) Nov 11
OptiNose, Inc. Provides Revenue Guidance for the Full Year 2022 Nov 11
OptiNose, Inc. Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting Nov 10
OptiNose, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 08
CEO & Director recently sold €190k worth of stock Sep 22
High number of new directors Sep 17
OptiNose, Inc. Provides Revenue Guidance for the Full Year of 2022 Aug 12
OptiNose, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 09
Optinose Announces XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program Jul 14
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program Jul 09
Optinose Announces Positive Top-Line Results of Reopen2, Its Second Phase 3 Clinical Trial of Xhance for Treatment of Chronic Sinusitis Jun 14 OptiNose, Inc. Announces Executive Appointments
Optinose, Inc. Updates Revenue Guidance for 2022 May 13
OptiNose, Inc. to Report Q1, 2022 Results on May 12, 2022 May 06
OptiNose, Inc., Annual General Meeting, Jun 08, 2022 May 02
Optinose Announces Appointment of R. John Fletcher to its Board of Directors as a Class III Director Apr 27 OptiNose, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022
OptiNose, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Mar 06 OptiNose, Inc.(NasdaqGS:OPTN) dropped from Russell 3000E Index Optinose Provides Update on Chronic Sinusitis Clinical Trials
Optinose, Inc. Expects Top-Line Results from One of Its Clinical Trials Evaluating XHANCE as A Potential Treatment for Chronic Sinusitis by the End of 2021 Mar 05
OptiNose, Inc. Enters into Amendment No. 1 to that Certain Manufacture and Supply Agreement with Contract Pharmaceuticals Limited Feb 26
OptiNose, Inc. to Report Q4, 2020 Results on Mar 03, 2021 Feb 18
Optinose Announces Board Changes Dec 02
Optinose, Inc. Announces Management Changes Nov 13
OptiNose Notifies Nasdaq That It Intends to Appoint A Third Member to the Company’s Audit Committee Sep 19 OptiNose, Inc. has completed a Follow-on Equity Offering in the amount of $35.1 million. Aug 15
Shareholder Returns 0OP0 DE Pharmaceuticals DE Market 7D 0% 2.5% 1.3% 1Y -65.4% -15.2% 9.0%
See full shareholder returns
Return vs Market: 0OP0 underperformed the German Market which returned 9% over the past year.
Price Volatility Is 0OP0's price volatile compared to industry and market? 0OP0 volatility 0OP0 Average Weekly Movement 842.7% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0OP0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0OP0's weekly volatility has increased from 409% to 843% over the past year.
About the Company OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.
Show more OptiNose, Inc. Fundamentals Summary How do OptiNose's earnings and revenue compare to its market cap? 0OP0 fundamental statistics Market cap €51.97m Earnings (TTM ) -€30.40m Revenue (TTM ) €73.86m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0OP0 income statement (TTM ) Revenue US$75.67m Cost of Revenue US$7.41m Gross Profit US$68.26m Other Expenses US$99.41m Earnings -US$31.15m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.10 Gross Margin 90.21% Net Profit Margin -41.16% Debt/Equity Ratio -306.6%
How did 0OP0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/11 18:38 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources OptiNose, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gary Nachman BMO Capital Markets Equity Research John Tanner Cantor Fitzgerald & Co. Matthew Caufield H.C. Wainwright & Co.
Show 6 more analysts 
